A preclinical Waltham biotech co-founded by noted Harvard immunologist Tim Springer is planning to begin trading on the stock market in the coming months.

Morphic filed documents with the SEC Friday for an $86.25 million IPO. It plans to trade on Nasdaq with the ticker “MORF”.

The biotech is developing a handful of drugs for diseases that involve fibrosis, or scarring, including Crohn’s Disease, the lung condition idiopathic pulmonary fibrosis and others.

Since its founding in 2015, Morphic…

Boston Biz Journal https://www.bizjournals.com/boston/news/2019/05/31/morphic-joins-may-biotech-ipo-push-with-86m-goal.html?ana=RSS&s=article_search